Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 Cream in Epidermolysis Bullosa
NCT02384460Phase 3Completed
- Sponsor
- Scioderm
- Start
- Mar 2015
- Primary completion
- Jul 2017
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of nelitolimod in epidermolysis bullosa (EB) (2 arms), sponsored by Scioderm. Primary endpoints: Time To Complete Target Wound Closure Within 3 Months and The Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months. Started Mar 2015; status: completed.
02
Drugs
nelitolimod
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT02384460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384460.